Therefore, a variety of methods have been developed to prolong the half-life and weaken the limitations of the treatment window, while harnessing the immunostimulatory effects and overcoming unfavorable Treg toxicity of IL-2 for patients suffering from malignant tumors. The gene discussed is IL2; the disease is cancer.